[Tumor response in comparative trials].
Survival improvement is the main aim of most cancer trials. Tumor response is a very common end-point in this context, as it permits a quick answer. It is useful criterion for screening in phase II trials, but cannot be utilised in phase III comparative trials for several reasons put forward in this article.
Département de biostatistique et d'épidémiologie, institut Gustave-Roussy, Villejuif, France.
A
A
Laplanche
D003627:Data Interpretation, Statistical; D004305:Dose-Response Relationship, Drug; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000401:mortality; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis
La résponse tumorale dans les essais comparatifs.